<DOC>
	<DOCNO>NCT00947492</DOCNO>
	<brief_summary>PBMNC DNA consider limit patient develop EBV associate post transplant lymphoproliferative disorder . show methotrexate tend decrease EBV load time , reach significance TNFa inhibitor significantly modify EBV load time . Our objective monitor Epstein Barr Virus load time patient Rheumatoid arthritis Orencia* ( abatacept ) RoActemra* ( tocilizumab ) , detect possible immunosuppression associate EBV dysregulation , see post transplant lymphoproliferative disease .</brief_summary>
	<brief_title>Monitoring Epstein-Barr Virus ( EBV ) Load Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs</brief_title>
	<detailed_description>Current treatment RA routinely include potentially immunosuppressive medication like methotrexate TNFa inhibitor . New immunosuppressive drug disposal , Orencia* ( abatacept ) T cell co-stimulation modulator ( CTLA4Ig ) RoActemra* ( tocilizumab ) , antibody IL6 receptor . In solid organ transplant recipient immunosuppressant , emergence lymphoma predict monitoring EBV load peripheral blood mononuclear cell ( PBMNCs ) . EBV load 1000 copy per 500 ng PBMNC DNA consider limit patient develop EBV associate post transplant lymphoproliferative disorder , condition characterize polyclonal EBV positive B lymphocyte proliferation evolve EBV positive B cell lymphoma . In first study , show Rheumatoid arthritis patient 10 fold systemic EBV overload , similar observe healthy organ transplant recipient . More recently , show methotrexate tend decrease EBV load time , reach significance TNFa inhibitor significantly modify EBV load time . Our objective monitor Epstein Barr Virus load time patient Rheumatoid arthritis Orencia* ( abatacept ) RoActemra* ( tocilizumab ) , detect possible immunosuppression associate EBV dysregulation , see post transplant lymphoproliferative disease .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Rheumatoid arthritis patient treat new immunosuppressive drug : Orencia* ( abatacept ) RoActemra* ( tocilizumab ) Disease longer one year Rheumatoid arthritis patient treat ciclosporin two year precede study Transplanted patient Disease short one year Histories lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rheumatoid Arthritis patient</keyword>
	<keyword>treat new immunosuppressive drug : Orencia* ( abatacept ) RoActemra* ( tocilizumab ) .</keyword>
</DOC>